Zoledronate benefits extend to cardiovascular & cancer events

Benefits of the bisphosphonates may  extend beyond fracture prevention to include reductions in cardiovascular and cancer events and possibly mortality, according to a New Zealand trial. A more in-depth analysis of a six year trial of zoledronate in older women with osteopenia has found benefits on cardiovascular disease and some cancers consistent with those seen ...

Already a member?

Login to keep reading.

© 2021 the limbic